07/03/2024 – AB Science is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development Download PDF Post navigationPreviousPrevious post:Two financial analysis firms initiate coverage of AB ScienceNextNext post:New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseRelated PostsAB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 13, 2024Two financial analysis firms initiate coverage of AB ScienceMarch 6, 2024Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CETMarch 1, 2024AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALSFebruary 26, 2024AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyJanuary 26, 2024
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALSApril 3, 2024
New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative diseaseMarch 13, 2024
AB Science announces that Health Canada has issued a Notice of Deficiency-Withdrawal (NOD/w) for masitinib in ALSFebruary 26, 2024
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines AgencyJanuary 26, 2024
